India has approved the sale of generic versions of hepatitis C drugs. The move will bring down the standard course of sofosbuvir and ledipasvir (generic versions of Sovaldi and Harvoni) to $1000 compared to $90,000 in United states and Europe.

http://ift.tt/1NgkVE1

Submitted November 29, 2015 at 03:03PM by KRISHNA53 http://ift.tt/1XoLC4D